Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

June 21, 2018 NEW YORK, June 21, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has initiated a food effect study in the U.S. for its

Oramed Patent Allowed in the US for Oral Administration of Proteins

Oramed Patent Allowed in the US for Oral Administration of Proteins

NEW YORK, May 30, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins,” has been allowed